πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11433053

LSD1 inhibitor and preparation method and application thereof

Medshine Discovery Inc. Β· Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11432547

Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer usin

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11427581

JAK inhibitor and use thereof

ZHUHAI UNITED LABORATORIES CO., LTD. Β· Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11426420

Inhibitors of short-chain dehydrogenase activity for treating coronary disorders

The Board of Regents of the University of Texas System Β· Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11426393

Prolyl hydroxylase inhibitors and methods of use

Akebia Therapeutics, Inc. Β· Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11426368

Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11420965

Pyrimidine compound as JAK kinase inhibitor

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11420936

Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases

NIKANG THERAPEUTICS, INC. Β· Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11414489

Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

HALOZYME, INC. Β· Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11414379

SPAK kinase inhibitors as neuroprotective agents

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11406713

Xanthine oxidase inhibitor formulations

XORTX THERAPEUTICS, INC. Β· Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11407998

Twist signaling inhibitor compositions and methods of using the same

The Regents of the University of California Β· Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11407736

RIP1 inhibitory compounds and methods for making and using the same

Rigel Pharmaceuticals, Inc. Β· Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11407723

Selective histone deacetylase inhibitors for the treatment of human disease

Shuttle Pharmaceuticals, Inc. Β· Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11407712

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2Ξ±

Arcus Biosciences, Inc. Β· Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11401286

Heteroaryl inhibitors of PDE4

Tetra Discovery Partners Β· Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11401246

Triazole glycolate oxidase inhibitors

Century Therapeutics, Inc. Β· Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11390646

Structure-based peptide inhibitors of Ξ±-synuclein aggregation

The Regents of the University of California Β· Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11390631

Benzodiazepine derivatives as RSV inhibitors

Enanta Pharmaceuticals, Inc. Β· Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11389433

BRD4 inhibitor treatment of IgE-mediated diseases

The Board of Regents of the University of Texas System Β· Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11384076

Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT

UniversitΓ€t Regensburg Β· Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11384065

Heterocyclic compound as CSF-1R inhibitor and use thereof

Medshine Discovery Inc. Β· Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11384055

Glycolate oxidase inhibitors for the treatment of disease

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11382955

Long-acting VEGF inhibitors for intraocular neovascularization

The Regents of the University of California Β· Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted